Abstract Library

#4532 Gender differences in patients with medullary thyroid cancer (MTC): A single-centre experience

Introduction: Medullary thyroid cancer (MTC) accounts for 3-5% of thyroid tumours. It can be sporadic or associated with genetic syndrome. The role of gender in the MTC isn’t clarified.

Conference:

Presenting Author:

Authors: Cannavale G, Minotta R, Liccardi A, Benevento E, Di Iasi G,

Keywords: MTC, gender difference, gender medicine,

#4337 Differences in plasma concentrations of selected growth factors in endocrine neoplasms – A pilot study

Introduction: Serum levels of growth factors associated with endocrine tumours may be potentially useful in detecting their recurrence.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Kurzynska A, Morawiec-Slawek K, Stefanska A, Kolasa M,

Keywords: growth factor, endocrine tumour, TNF-α, Fascin, recurrence risk,

#4216 Immunohistochemical analysis for galectin-3 and outcomes in medullary thyroid cancer

Introduction: Galectin-3 (Gal-3) is a beta-galactoside involved in multiple biological and pathological processes including growth and differentiation, cellular adhesion and transformation, and metastatic potential.

Conference:

Presenting Author: Raia S

Authors: Raia S, Chiloiro S, Giampietro A, Lugli F, Maratta M,

Keywords: Thyroid, MTC, Galectine3,

#3797 Evaluation of neutrophile to lymphocyte and platelet to lymphocyte ratio in patients with medullary thyroid cancer (MTC)

Introduction: Medullary thyroid cancer (MTC) is a rare neoplasm in which the investigation of new biomarkers is essential. An elevated neutrophile to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) has been proposed as a negative prognostic factor in several neoplasms, but their role in MTC is unclear.

Conference:

Presenting Author:

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Modica R,

Keywords: neuroendocrine tumor, biomarker, medullary thyroid carcinoma, mtc, nlr, plr,

#3273 LIBRETTO-531: Selpercatinib vs standard of care in patients (pts) with multikinase inhibitor-naïve advanced or metastatic RET-mutant (mut) medullary thyroid cancer (MTC)

Introduction: Multikinase inhibitors (MKI) are approved for MTC; however, their efficacy in RETmut MTC is limited due to incomplete RET inhibition and significant toxicity. Selpercatinib (LOXO-292), a highly selective and potent FDA approved inhibitor of RET alterations including M918T, MKI resistance-associated V804M, and others, showed robust, durable clinical activity with a tolerable profile in pts with RETmut MTC in the Phase 1/2 LIBRETTO-001 study.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Leboulleux S, Robinson B, Hoff A, Brose M, Wirth L,

Keywords: RET alteration, medullary thyroid cancer (MTC), phase 3 trial, selpercatinib,